PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
74.78%
Positive EBIT growth while CRVO is negative. John Neff might see a substantial edge in operational management.
74.78%
Positive operating income growth while CRVO is negative. John Neff might view this as a competitive edge in operations.
64.85%
Net income growth above 1.5x CRVO's 5.89%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
64.71%
EPS growth above 1.5x CRVO's 5.89%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
64.71%
Diluted EPS growth above 1.5x CRVO's 5.89%. David Dodd would see if there's a robust moat protecting these shareholder gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-60.52%
Negative OCF growth while CRVO is at 78.96%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-60.52%
Negative FCF growth while CRVO is at 78.96%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
51.61%
OCF/share CAGR of 51.61% while CRVO is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
51.61%
OCF/share CAGR of 51.61% while CRVO is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
51.61%
3Y OCF/share CAGR of 51.61% while CRVO is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
66.06%
10Y net income/share CAGR of 66.06% while CRVO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
66.06%
Positive 5Y CAGR while CRVO is negative. John Neff might view this as a strong mid-term relative advantage.
66.06%
Positive short-term CAGR while CRVO is negative. John Neff would see a clear advantage in near-term profit trajectory.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.06%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-5.28%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
11.50%
We have some new debt while CRVO reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-73.61%
We cut SG&A while CRVO invests at 24.82%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.